Weight loss and diabetes drugs in the class called GLP-1s have exploded onto the market, starting to put a real dent in the obesity epidemic. And as doctors are gathering more data, it looks like the medications may also provide real benefits for cardiac health, liver disease, kidney function and possibly even addiction and sleep disorders. In this episode, a panel of experts explains how the drugs work, why they’ve been so effective, and how hopeful we might be about other uses. Cedars Sinai cardiologist Martha Gulati joins Nora Volkow, the director of the National Institute on Drug Abuse and Diana Thiara, an obesity expert at UCSF, for a forward-looking conversation about this potentially game-changing medical advancement. Time Magazine health reporter Alice Park moderates the conversation.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Is There Anything GLP-1s Can’t Do?

Aspen Ideas to Go

AI Chapters

AI Insights

Reviews